TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04652115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Deibrotide via IV
Study: NCT05483439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Description: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)

Intervention type: DRUG
Group type: OTHER
Intervention: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Description: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Study: NCT04661995

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hearing Aid and Notched Noise Therapy
Description: Notched Noise Therapy involves presenting wide-band sound with the tinnitus frequency region notched out, referred to as notched noise, or notch therapy. This procedure may distribute lateral inhibition into the notched frequency region, suppressing tinnitus neural activity believed to be occurring there. This type of therapy is provided through a sound file that is streamed through hearing aids.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid and Broadband Noise
Description: Broadband Noise, or white noise, is a common tinnitus sound therapy treatment option. It is also commonly used as a masker noise for individuals with tinnitus that like to enrich their environment with sound.
Study: NCT05483439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional herbal medicine
Description: traditional herbal medicine
Study: NCT04976049

Intervention type: PROCEDURE
Intervention: Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery
Description: Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
Study: NCT06259929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG + Giredestrant 30 MG
Description: Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
Study: NCT05824156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 mg/kg CM-101
Description: CM-101, Monoclonal Ab blocking CCL24

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06044259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMDS; Artivion, Atlanta, Georgia, US
Description: Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemiarch replacement
Description: Coventional open hemiarch replacement
Study: NCT05741268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Description: 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical behavior therapy
Description: 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
Study: NCT06392022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching cartoons with music
Description: The purpose of this study was to evaluate the effect of watching musical cartoons on anxiety and vital signs in children undergoing rectal irrigation.
Study: NCT06209190

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow and total lymphoid irradiation
Description: doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system plus conditioning scheme of our institution
Study: NCT04661995

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hearing Aid
Description: A-O groups will use ear-level, self-contained devices (hearing aids) that (1) are capable of streaming shapeable broadband noise between 1-10 kHz; (2) allow for normal conversation; and (3) are comfortable, easy to use, and discrete. These criteria describe a behind-the-ear hearing aid with the capability of streaming custom sounds. Hearing aids are used to provide amplification to those with hearing loss and are fit by licensed audiologists. Sometimes, hearing aids can provide benefit to those with bothersome tinnitus.
Study: NCT04593888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten reduced diet
Description: Dietary advice focusing on reducing gluten intake in children
Study: NCT06092996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time of Sling Use
Description: Standard sling worn for only three days post operatively
Study: NCT05147818

Intervention type: OTHER
Intervention: CBC ,renal function tests , fundus Examination
Description: Laboratory investigations
Study: NCT05266911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity functional strength training
Description: HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lower extremity stretching
Description: Lower extremity stretching program to be completed by participants at home 3 days per week.
Study: NCT05550558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Camrelizumab
Description: Anlotinib PO plus Camrelizumab IV
Study: NCT04820673

Intervention type: DRUG
Intervention: Sarecycline
Description: Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
Study: NCT04901611

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parental touch
Description: Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental touch
Description: Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
Study: NCT05526001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELIXCYTE
Description: ELIXCYTE, a new investigational product developed by UnicoCell Biomed, contains allogenic Adipose-derived stem cells (ADSCs). The ADSCs of ELIXCYTE for subjects were obtained from donors, and the Sponsor followed the manufacturing and testing procedures described in chemistry, manufacturing and control (CMC) information in order to assure the quality of final products.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo control used in the study.
Study: NCT05948150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using a breastfeeding pillow
Description: To make the breastfeeding pillow group use the breastfeeding pillow from the 8th hour in the postnatal period and to make evaluations at 24 and 48 hours
Study: NCT04564833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous administration
Study: NCT04897295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
Study: NCT06263465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus cispatus
Description: 10\^9 cfu,5 days
Study: NCT04897295

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
Study: NCT06263465

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0 cfu,5 days
Study: NCT05934045

Intervention type: BIOLOGICAL
Intervention: RNAseq
Description: there is no intervention done.
Study: NCT05948150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: not using a breastfeeding pillow
Description: The non-breastfeeding pillow group was evaluated at 24 and 48 hours without the use of a breastfeeding pillow
Study: NCT05159531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
Study: NCT04812704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Patient receive protein supplement in liquid form after each exercice session
Study: NCT06530082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CircFam53B-219aa DC vaccine
Description: Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CircFam53B-219aa DC vaccine
Description: Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.
Study: NCT05159531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP
Description: Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Model of Care
Description: Freddie® allows for asynchronous contact between patients and care providers, meaning that it does not require both groups to be connected in real time, instead allowing communication over a number of days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Delivery of PrEP care through the local standard of care
Study: NCT05685147

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Non-invasive Preimplantation genetic testing for aneuploidy status
Description: In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
Study: NCT05105477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcumenTM HPI Software Feature
Description: The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
Study: NCT05986604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support Intervention
Description: The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.
Study: NCT05105477

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-protocolized Standard of Care
Description: Non-protocolized standard of care to treat subjects
Study: NCT05986604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.
Study: NCT04627766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with VT-Patch (Connected device manufactured by VitalTracer)
Description: Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
Study: NCT04992260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlled vaccine
Description: The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
Study: NCT05870098

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: All participants
Description: 1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine.
Study: NCT05932069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIN
Description: Stationary cycling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic, stretching/balance intervention Control
Description: Balance and stretching exercise
Study: NCT05368233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS protocol
Description: ERAS protocol whch helps to optimise the length of hospital stay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: ERAS protocol whch helps to optimise the length of hospital stay.
Study: NCT04668222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yu-Ping-Feng formula
Description: Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yu-Ping-Feng formula
Description: Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiang-Sha-Liu-Jun formula
Description: Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liu-Wei-Di-Huang formula
Description: Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Deficiency of Qi and Yang
Description: Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Deficiency of Qi and Yin
Description: Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula
Study: NCT06306794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crochet octopus
Description: During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure.
Study: NCT05084534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)
Study: NCT04905719

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
Study: NCT04249063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 1 % and Normal Saline
Description: 3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
Study: NCT05485857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arrangement of small intestine order before close the abdomen
Description: After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterward, close the abdomen.
Study: NCT06330428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexuality-Based Family Planning Education via Podcast
Description: The training program is planned to consist of 5 modules. These trainings will be shared module by module on a daily basis through an application (Spotify) where podcasts are shared. These modules are as follows: 1. Sexual and Reproductive Health / Sexual Rights / Female-Male / Physiology of Sexual Functions, 2. Sexual Myths, 3. Contraceptive Methods-1, 4. Contraceptive Methods-2, 5. Sexually Transmitted Diseases / Safe Sexual Intercourse As a result of randomization, the links of the podcasts will be shared with the women in the experimental group one by one on a daily basis. Podcasts are planned to last an average of 10 minutes. This training content is planned for 5 days and the second tests will be applied by the researcher to the women who finish the podcasts. The 3rd tests will be applied 4 weeks after the second tests.
Study: NCT06452823

Intervention type: PROCEDURE
Intervention: Catheter Ablation
Description: catheter radiofrequency ablation therapy for atrial fibrillation involves the use of ablative energy to destroy the cardiomyocytes at the opening of the pulmonary veins, which blocks the electrical conduction pathway between the pulmonary veins and the left atrium, so that atrial fibrillation no longer occurs.
Study: NCT05469893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Intravenous (IV) dosage and timing per protocol design
Study: NCT04452461

Intervention type: DRUG
Group type: OTHER
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine / Nab-paclitaxel
Description: Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.